Clinical Trials
8 trialsNCT03382977 2026-05-08
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
VBI Vaccines Inc.
Phase 1/2 Terminated
NCT04421378 2024-12-16
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
Phase 1/2 Terminated
NCT00814593 2019-05-10
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery
Lisata Therapeutics, Inc.
Phase 2 Withdrawn
NCT00761280 2014-11-14
SAPPHIRE
Isarna Therapeutics GmbH
Phase 3 Terminated
NCT01656980 2012-08-03
Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase 3 Unknown
NCT01637753 2012-07-11
Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase NA Unknown
NCT00076986 2011-06-06
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
INSYS Therapeutics Inc
Phase 3 Completed
NCT00068952 2008-04-01
Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme
Pfizer
Phase 3 Completed